GordonMGlobal Investments, Sanofi Ventures and Viking Global Investors led a $125m Series D round in Star Therapeutics.

GordonMD Global Investments, Sanofi Ventures and Viking Global Investors led a $125m Series D round in Star Therapeutics, a biotechnology company engaged in discovering and developing novel therapies for rare diseases through its portfolio of innovative biotech companies, with participation from Janus Henderson Investors and Frazier Life Sciences. The financing will fuel the continued advancement of Star’s pipeline, including its lead program, VGA039. VGA039 is an antibody that targets Protein S to restore balance in blood clotting. It is being developed as a universal therapy for bleeding disorders, starting with von Willebrand Disease (VWD). A pivotal Phase 3 trial of VGA039 in VWD patients is now underway.